SGRY Stock Analysis: Surgery | NASDAQ
Medical Care Facilities | NASDAQ, USA | Market Cap: 3.508m USD | 12M Return: 69.9% | US86881A1007 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 108M
EPS Trend: -90.1%
Qual. Beats: 3
Rev. Trend: 95.7%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 11.1 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Surgery Partners, Inc. (NASDAQ: SGRY) owns and operates a U.S. network of ambulatory surgery centers and surgical hospitals that provide non-emergency procedures across specialties including orthopedics, ophthalmology, gastroenterology, and general surgery. Founded in 2004 and headquartered in Brentwood, Tennessee, the company also offers ancillary services such as physician practices, diagnostic testing, urgent care facilities, and anesthesia services, operating both single- and multi-specialty locations.
The company operates within the healthcare facilities sub-industry, where ambulatory surgery centers have grown as a lower-cost outpatient alternative to hospital-based procedures. Surgery Partners completed its IPO on October 1, 2015, and is classified as a small-cap stock with a market capitalization of approximately $1.89 billion USD.
- Outpatient surgical case volumes accelerate as procedures shift from hospitals
- Adjusted EBITDA margin expansion drives profitability
- Leverage reduction and refinancing lower interest expense
| Net Income: -87.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 0.43 > 1.0 |
| NWC/Revenue: 17.30% < 20% (prev 15.70%; Δ 1.60% < -1%) |
| CFO/TA 0.04 > 3% & CFO 277.9m > Net Income -87.0m |
| Net Debt (3.22b) to EBITDA (667.4m): 4.82 < 3 |
| Current Ratio: 2.17 > 1.5 & < 3 |
| Outstanding Shares: last quarter (128.9m) vs 12m ago 1.52% < -2% |
| Gross Margin: 21.10% > 18% (prev 23.92%; Δ -2.81% > 0.5%) |
| Asset Turnover: 44.81% > 50% (prev 41.38%; Δ 3.43% > 0%) |
| Interest Coverage Ratio: 1.22 > 6 (EBIT TTM 490.1m / Interest Expense TTM 400.8m) |
| A: 0.08 (Total Current Assets 1.08b - Total Current Liabilities 498.6m) / Total Assets 7.05b |
| B: -0.13 (Retained Earnings -887.3m / Total Assets 7.05b) |
| C: 0.07 (EBIT TTM 490.1m / Avg Total Assets 7.50b) |
| D: 0.40 (Book Value of Equity 1.66b / Total Liabilities 4.15b) |
| Altman-Z'' = 0.99 = BB |
| DSRI: 0.79 (Receivables 468.1m/579.3m, Revenue 3.36b/3.29b) |
| GMI: 1.13 (GM 23.92% / 21.10%) |
| AQI: 1.02 (AQ_t 0.70 / AQ_t-1 0.68) |
| SGI: 1.02 (Revenue 3.36b / 3.29b) |
| TATA: -0.05 (NI -87.0m - CFO 277.9m) / TA 7.05b) |
| Beneish M = -3.05 (Cap -4..+1) = AA |
As of November 20, 2026, the stock is trading at USD 26.69 with a total of 2,731,496 shares traded. Over the past week, the price has changed by +0.41%, over one month by +81.44%, over three months by +96.25% and over the past year by +69.89%.
Current recommended Stop Loss: 25.90 (which is 3% or 1.2 ATR below the current price).
Surgery has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold SGRY.
- StrongBuy: 0
- Buy: 0
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 24.4 | -8.6% |
P/E Forward = 666.6667
P/S = 1.0439
P/B = 2.1205
P/EG = 1.66
Revenue TTM = 3.36b USD
EBIT TTM = 490.1m USD
EBITDA TTM = 667.4m USD
Long Term Debt = 3.00b USD (from longTermDebt, last quarter)
Short Term Debt = 89.6m USD (from shortTermDebt, last quarter)
Debt = 3.57b USD (from shortLongTermDebtTotal, last quarter) + Leases 257.5m
Net Debt = 3.22b USD (calculated: Debt 3.57b - CCE 354.5m)
Enterprise Value = 6.72b USD (3.51b + Debt 3.57b - CCE 354.5m)
Interest Coverage Ratio = 1.22 (Ebit TTM 490.1m / Interest Expense TTM 400.8m)
EV/FCF = 33.15x (Enterprise Value 6.72b / FCF TTM 202.8m)
FCF Yield = 3.02% (FCF TTM 202.8m / Enterprise Value 6.72b)
FCF Margin = 6.04% (FCF TTM 202.8m / Revenue TTM 3.36b)
Net Margin = -2.59% (Net Income TTM -87.0m / Revenue TTM 3.36b)
Gross Margin = 21.10% ((Revenue TTM 3.36b - Cost of Revenue TTM 2.65b) / Revenue TTM)
Gross Margin QoQ = 22.69% (prev 22.41%)
Tobins Q-Ratio = 0.95 (Enterprise Value 6.72b / Total Assets 7.05b)
Interest Expense / Debt = 11.23% (Interest Expense 400.8m / Debt 3.57b)
Taxrate = 20.83% (18.6m / 89.3m)
NOPAT = 388.0m (EBIT 490.1m * (1 - 20.83%))
Current Ratio = 2.17 (Total Current Assets 1.08b / Total Current Liabilities 498.6m)
Debt / Equity = 2.14 (Debt 3.57b / totalStockholderEquity, last quarter 1.66b)
Debt / EBITDA = 4.82 (Net Debt 3.22b / EBITDA 667.4m)
Debt / FCF = 15.86 (Net Debt 3.22b / FCF TTM 202.8m)
Total Stockholder Equity = 1.68b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.16% (Net Income -87.0m / Total Assets 7.05b)
RoE = -5.17% (Net Income TTM -87.0m / Total Stockholder Equity 1.68b)
RoCE = 10.47% (EBIT 490.1m / Capital Employed (Equity 1.68b + L.T.Debt 3.00b))
RoIC = 5.99% (NOPAT 388.0m / Invested Capital 6.47b)
WACC = 7.99% (E(3.51b)/V(7.08b) * Re(7.07%) + D(3.57b)/V(7.08b) * Rd(11.23%) * (1-Tc(0.21)))
Discount Rate = 7.07% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.01 | Cagr: 0.96%
[DCF] Terminal Value 76.01% ; FCFF base≈199.3m ; Y1≈207.6m ; Y5≈236.6m
[DCF] Fair Price = 3.33 (EV 3.65b - Net Debt 3.22b = Equity 436.0m / Shares 130.9m; r=8.35% [WACC [floored]]; 5y FCF grow 4.48% → 2.50% )
EPS Correlation: -90.10 | EPS CAGR: -39.10% | SUE: 2.56 | # QB: 3
Revenue Correlation: 95.71 | Revenue CAGR: 8.19% | SUE: 4.0 | # QB: 1
EPS current Quarter (2027-03-31): EPS=0.02 | Chg30d=+133.33% | Revisions=+0% | Analysts=1
EPS current Year (2026-12-31): EPS=0.41 | Chg30d=+18.09% | Revisions=+0% | GrowthEPS=-12.1% | GrowthRev=-3.4%
EPS next Year (2027-12-31): EPS=0.20 | Chg30d=-28.54% | Revisions=+25% | GrowthEPS=-51.6% | GrowthRev=-8.6%
[Analyst] Revisions Ratio: +25% (up=1, down=0)